US EditionEli Lilly and Biogen/Eisai’s Extension Trials Make Waves in Alzheimer’s Market
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.5 Articles
5 Articles
Eli Lilly has announced the results of the long-term extension (LTE) of phase 3 study TrailBLAZER-ALZ 2, which show that participants treated with donanemab experienced a slowdown in cognitive impairment, a benefit that continued to increase over three years compared to an untreated external cohort of the Alzheimer’s Disease Neuroimaging Initiative (ADNI). These data have just been presented during the 2025 Alzheimer’s Association International …
Donanemab, by Eli Lilly, has shown increasing benefits to three years in the treatment of early symptomatic Alzheimer's disease, according to the results of the long-term extension of the phase 3 trial 'Trailblazer-Alz 2', which emphasizes that patients given the drug experienced a slowing down of cognitive impairment.These data have been presented during the International Conference of the Alzheimer's Association (AAIC), held in Toronto, Canada.
Eli Lilly and Biogen/Eisai’s extension trials make waves in Alzheimer’s market
Eli Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after over three years of treatment.The post Eli Lilly and Biogen/Eisai’s extension trials make waves in Alzheimer’s market appeared first on Clinical Trials Arena.
Eli Lilly Trial Shows Sustained Benefits and Stable Safety Profile for Limited-Duration Alzheimer’s Treatment
A recent extension trial has revealed long-term benefit […] The post Eli Lilly Trial Shows Sustained Benefits and Stable Safety Profile for Limited-Duration Alzheimer’s Treatment first appeared on GeneOnline News. The post Eli Lilly Trial Shows Sustained Benefits and Stable Safety Profile for Limited-Duration Alzheimer’s Treatment appeared first on GeneOnline News.
New data for Alzheimer’s drugs raise hopes, and questions, about bigger benefits over time
TORONTO — Two studies following Alzheimer’s patients for several years after starting Eli Lilly and Eisai's amyloid-clearing treatments suggest the benefits are magnified over time, bolstering the companies’ arguments that the full benefits of the drugs ...
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
